UNSPSC 51421603: Diflorasone

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28F2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier T2DHJ9645W, chemically known as 6alpha-fluorobetamethasone-17,21 diacetate but generally known as diflorasone, which bears US NIH Compound Identifier 71414. European Medicines Agency schedules Diflorasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07126MIG.

UNSPSC 51421603 Diflorasone (Commodity) represents a specific pharmaceutical product, yet the recent state and local opportunities tagged under this code show minimal direct relevance to diflorasone procurement itself. Instead, the opportunities reflect broader pharmaceutical and medication-acquisition activities that state and local health agencies are pursuing. The Seminole County, Florida IFB seeks naloxone and safe drug deactivation systems — distinct medications and paraphernalia for opioid overdose response and controlled substance disposal — while the Texas Health and Human Services Commission's RFI explores direct-to-manufacturer prescription programs to bypass traditional pharmacy benefit manager intermediaries. State and local issuing bodies using this code include county health departments and state health and human services commissions, suggesting that the code may be applied as a catch-all for pharmaceutical acquisitions that do not fit narrower commodity categories, or that tagging practices vary by jurisdiction.

Geographic activity centers on Florida and Texas based on recent solicitations. The Seminole County opportunity (IFB 60459723LAS, due July 26, 2023) calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building, while the Texas HHS Commission RFI (HHS0017013, posted April 3, 2026) seeks vendor input on direct pharmaceutical contracting models. The mismatch between the code's nominal scope and the substance of recent opportunities — naloxone, drug deactivation systems, and direct-prescription contracting versus diflorasone, a specific corticosteroid — suggests either inconsistent code application or that this Commodity code is rarely procured directly by state and local governments in its specified form.